Inadequate Efficacy and Safety Reporting for FDA-Cleared AI/ML-Enabled Medical Devices (2026)
OVERVIEWA 2026 analysis of FDA-cleared AI and machine learning-enabled medical devices found pervasive inadequacy in efficacy and safety reporting, with most cleared devices lacking detailed information about performance characteristics, failure modes, or safety limitations. This transparency gap undermines clinical decision-making and prevents healthcare organizations from making informed deployment choices. Manufacturers frequently submit vague claims about device performance without specifying conditions under which the AI system may fail, populations in which it performs poorly, or edge cases where human oversight is critical. Safety reports are often minimal, focused on analytical validation rather than real-world clinical risks. The FDA's clearance summaries—which are public documents—frequently lack the detail necessary for clinicians to understand when and how to use the device safely. This inadequate reporting creates liability exposure for healthcare organizations deploying these devices. Institutions may face malpractice claims if AI-assisted decisions harm patients, yet they lack complete information about the device's known limitations. Improving this landscape requires stronger FDA requirements for transparency in device labeling, post-market surveillance data sharing, and clinician education about AI system limitations. Until reporting standards improve, healthcare organizations should treat AI device claims with skepticism and demand independent validation before…
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.